JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Innoviva Inc

Chiusa

SettoreSettore sanitario

17.55 -1.13

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.38

Massimo

17.8

Metriche Chiave

By Trading Economics

Entrata

110M

64M

Vendite

12M

100M

P/E

Media del settore

30.193

37.461

Margine di Profitto

63.508

Dipendenti

127

EBITDA

111M

84M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+114.81% upside

Dividendi

By Dow Jones

Utili prossimi

4 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-82M

1.1B

Apertura precedente

18.68

Chiusura precedente

17.55

Notizie sul Sentiment di mercato

By Acuity

34%

66%

97 / 373 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Innoviva Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 ott 2025, 23:50 UTC

Azioni calde

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 ott 2025, 23:25 UTC

Utili

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 ott 2025, 23:18 UTC

Utili

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 ott 2025, 22:20 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 ott 2025, 22:13 UTC

Utili

Wal-Mart de Mexico Net Profit Falls in 3Q

28 ott 2025, 21:38 UTC

Utili

Correction to Visa Sales Jump Article

28 ott 2025, 21:17 UTC

Utili

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 ott 2025, 21:07 UTC

Utili

Visa Sales Jump as Consumers Keep Spending -- Update

28 ott 2025, 21:02 UTC

Utili

Mondelez Tempers Outlook as Costs Rise

28 ott 2025, 23:51 UTC

Discorsi di Mercato

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 ott 2025, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 ott 2025, 23:02 UTC

Utili

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 ott 2025, 23:01 UTC

Utili

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 ott 2025, 22:46 UTC

Utili

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 ott 2025, 22:45 UTC

Utili

SK Hynix 3Q Net KRW12.6T >000660.SE

28 ott 2025, 22:44 UTC

Utili

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 ott 2025, 22:43 UTC

Utili

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 ott 2025, 22:42 UTC

Utili

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 ott 2025, 22:40 UTC

Utili

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 ott 2025, 22:22 UTC

Utili

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 ott 2025, 22:20 UTC

Utili

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 ott 2025, 22:02 UTC

Utili

Review & Preview: Earnings Extravaganza -- Barrons.com

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

28 ott 2025, 21:42 UTC

Discorsi di Mercato
Utili

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 ott 2025, 21:20 UTC

Utili

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 ott 2025, 21:19 UTC

Utili

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 ott 2025, 21:18 UTC

Utili

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Confronto tra pari

Modifica del prezzo

Innoviva Inc Previsione

Obiettivo di Prezzo

By TipRanks

114.81% in crescita

Previsioni per 12 mesi

Media 38 USD  114.81%

Alto 55 USD

Basso 17 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Innoviva Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

4 ratings

3

Acquista

0

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

18.57 / 18.75Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

97 / 373 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat